Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH)
CUSIP: 252828108
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 51,647,137
- Total 13F shares
- 39,106,709
- Share change
- +1,343,217
- Total reported value
- $728,558,630
- Put/Call ratio
- 22%
- Price per share
- $18.63
- Number of holders
- 101
- Value change
- +$24,440,177
- Number of buys
- 46
- Number of sells
- 53
Quarterly Holders Quick Answers
What is CUSIP 252828108?
CUSIP 252828108 identifies DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 252828108:
Top shareholders of DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
8.7%
|
4,482,609
|
$81,314,527 | — | 31 Mar 2025 | |
| Lei Meng |
3/4/5
|
Director |
—
mixed-class rows
|
4,557,387
mixed-class rows
|
$54,608,811 | — | 22 Jan 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
5.6%
|
2,866,733
|
$52,002,537 | — | 31 Mar 2025 | |
| Fairmount Funds Management LLC |
13F
3/4/5
|
Company · Director |
5.2%
|
2,700,691
|
$48,990,535 | — | 31 Mar 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
5.2%
|
2,689,707
|
$48,791,285 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
4.6%
|
2,357,702
|
$42,768,714 | — | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
4.5%
|
2,341,667
|
$42,477,839 | — | 31 Mar 2025 | |
| Third Rock Ventures IV, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,058,204
|
$36,698,448 | — | 07 Feb 2023 | |
| TCG Crossover GP II, LLC |
13D/G
|
— |
4.7%
|
1,501,624
|
$32,660,322 | $0 | 31 Mar 2025 | |
| VR Adviser, LLC |
13F
|
Company |
3.4%
|
1,744,373
|
$31,642,926 | — | 31 Mar 2025 | |
| Avidity Partners Management LP |
13F
|
Company |
3.3%
|
1,720,902
|
$31,217,162 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
3.3%
|
1,700,069
|
$30,839,252 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
3.1%
|
1,615,801
|
$29,310,631 | — | 31 Mar 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.9%
|
1,501,624
|
$27,239,459 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.9%
|
1,486,944
|
$26,973,164 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.1%
|
1,108,875
|
$20,114,992 | — | 31 Mar 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
3.1%
|
1,000,000
|
$20,060,000 | $0 | 30 Jun 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
2%
|
1,027,711
|
$18,642,678 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
2%
|
1,025,622
|
$18,604,783 | — | 31 Mar 2025 | |
| Moulder Leon O Jr. |
3/4/5
|
Director |
—
mixed-class rows
|
1,447,745
mixed-class rows
|
$17,240,940 | — | 23 May 2024 | |
| Catalio Capital Management, LP |
13F
|
Company |
1.5%
|
763,471
|
$13,849,364 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.5%
|
759,679
|
$13,780,577 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1.3%
|
683,616
|
$13,703,083 | — | 31 Mar 2025 | |
| Jason Gardner |
3/4/5
|
Title: President and Chief Executive Officer, Director |
—
class O/S missing
|
944,954
|
$11,339,448 | — | 30 Nov 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1%
|
517,018
|
$9,380,689 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.91%
|
470,880
|
$8,541,763 | — | 31 Mar 2025 | |
| BRAIDWELL LP |
13F
|
Company |
0.73%
|
375,355
|
$6,808,940 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.58%
|
300,504
|
$5,451,143 | — | 31 Mar 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.53%
|
275,000
|
$4,988,500 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.51%
|
264,692
|
$4,801,513 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.48%
|
248,610
|
$4,509,785 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.46%
|
235,533
|
$4,272,568 | — | 31 Mar 2025 | |
| Alphabet Inc. |
13F
|
Company |
0.4%
|
208,697
|
$3,785,764 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.37%
|
190,334
|
$3,452,659 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.37%
|
189,000
|
$3,428,460 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.33%
|
168,102
|
$3,049,370 | — | 31 Mar 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.25%
|
126,627
|
$2,297,014 | — | 31 Mar 2025 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.23%
|
116,997
|
$2,122,326 | — | 31 Mar 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.21%
|
106,931
|
$1,939,728 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.18%
|
93,287
|
$1,692,226 | — | 31 Mar 2025 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.16%
|
80,584
|
$1,461,794 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.15%
|
79,168
|
$1,436,108 | — | 31 Mar 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.15%
|
75,000
|
$1,360,500 | — | 31 Mar 2025 | |
| MOODY ALDRICH PARTNERS LLC |
13F
|
Company |
0.14%
|
74,372
|
$1,349,108 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.14%
|
73,638
|
$1,335,793 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.14%
|
73,430
|
$1,332,021 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.13%
|
67,982
|
$1,233,194 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.12%
|
64,381
|
$1,167,872 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.09%
|
47,817
|
$867,400 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.09%
|
47,429
|
$860,362 | — | 31 Mar 2025 |
Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) as of Q2 2025
As of 30 Jun 2025,
Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) was held by
101 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,106,709 shares.
The largest 10 holders included
FMR LLC, Vestal Point Capital, LP, RA CAPITAL MANAGEMENT, L.P., Fairmount Funds Management LLC, Bain Capital Life Sciences Investors, LLC, Octagon Capital Advisors LP, Deep Track Capital, LP, Avidity Partners Management LP, TCG Crossover Management, LLC, and VANGUARD GROUP INC.
This page lists
101
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
97
Q2 2025 holders
101
Holder diff
4
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.